{"id":"W4399483084","doi":"10.1136/annrheumdis-2024-eular.1527","title":"AB1428 ADALIMUMAB AND TOCILIZUMAB BIOSIMILARS IN EUROPE: BUDGET-IMPACT AND OPPORTUNITY FOR EXPANDED PATIENT ACCESS","year":2024,"lang":"en","type":"article","venue":"Annals of the Rheumatic Diseases","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":false,"ca_institutions":"EVERSANA (Canada)","funders":"","keywords":"Biosimilar; Adalimumab; Tocilizumab; Medicine; Internal medicine; Rheumatoid arthritis","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000312795,0.0001769094,0.0003549315,0.00009559607,0.00008476238,0.00006326971,0.0002173989,0.00009686157,0.0001421929],"category_scores_gemma":[0.0009185916,0.0001021274,0.0001360768,0.0002401332,0.0003285422,0.0001323777,0.0002277249,0.000112762,0.000001407966],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000009131166,"about_ca_system_score_gemma":0.0001275625,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00005470629,"about_ca_topic_score_gemma":0.00001499785,"domain_scores_codex":[0.9988065,0.0002698662,0.0003637206,0.0002499503,0.0000504753,0.0002594603],"domain_scores_gemma":[0.9988986,0.0006064401,0.00009316659,0.0002443809,0.00008239271,0.00007498882],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"observational","study_design_scores_codex":[0.001302148,0.0009264755,0.00915371,0.002283829,0.001358555,0.00001371793,0.001058972,0.00001058842,0.002408616,0.002098278,0.08497977,0.8944054],"study_design_scores_gemma":[0.009571244,0.004765386,0.7205509,0.01000279,0.001777201,0.0002282615,0.002301078,0.003369261,0.08414043,0.1024343,0.05833272,0.002526399],"study_design_candidate":"design_other","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9583697,0.0338999,0.00004685273,0.005732057,0.0003010827,0.0006505842,0.000734259,0.00003700471,0.0002285454],"genre_scores_gemma":[0.9965945,0.002350301,0.00004699291,0.0007970016,0.000005463036,0.0000285484,0.00001509525,0.00001388725,0.0001481752],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.891879,"threshold_uncertainty_score":0.4164636,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.07246973880904191,"score_gpt":0.3817156132756152,"score_spread":0.3092458744665733,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}